About
Pharmaceuticals
Adicet Bio Inc is a preclinical-stage biotechnology company engaged in the design and development of immunotherapies for cancer and other disease indications, with a focus on novel universal immune cell therapies. The company's development is based on gamma delta T cells engineered with chimeric antigen receptors or T-cell receptors. In 2016, Adicet Bio Inc acquired Israeli company Applied Immune Technologies (AIT), which develops immunotherapies. AIT, today called Adicet Bio Israel, continues its operations in Israel as Adicet's wholly owned subsidiary.
Identity
| Name | Adicet Bio |
|---|---|
| Slug | adicet-bio |
| Former names | resTORbio |
| Type / kind | multinational |
| Crunchbase ID | adicet-bio |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAoLmwuuoLDA |
Status
| Status | active |
|---|---|
| Status reason | Public on NASDAQ on Sep, 2020; |
| Last update | 2026-05-17 |
Location
| HQ country | United States |
|---|---|
| HQ country code | US |
| HQ address | Menlo Park, CA, USA |
Web & social
| Website | http://www.adicetbio.com |
|---|---|
| https://www.linkedin.com/company/10701436 |
Classifications
Tags
cell-therapypharmaceuticalscancerimmunology
Funding
| Total raised | — |
|---|---|
| Market cap | $1.3B |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}